← Dashboard
Dashboard / Strategy
🎯 Strategy

Brand Strategy & Business Development

The strategic backbone — Brad's playbook (exec summary → SWOT → dermatologist outreach), the evidence-backed SWOT, and the priorities that flow from it. Feeds go-to-market and advisor outreach.

On this page Positioning Personas Aperture Brad's Playbook SWOT Red Team Priorities Open Questions
Positioning THE SPINE
"For skin that feels everything."burned — used by 3 brands
Audience line: ⏸ parkedboth leading candidates rejected · brand language resumes later · clearance verdicts + threading criterion banked in Obsidian
For Australians with eczema and reactive skin who are tired of products that feel like medicine, Spanner Skin is sensory-first skincare that makes everyday care fast, calming, and genuinely nice to use — because looking after difficult skin shouldn't feel like a chore or a diagnosis.
ESSENCE: under review  ·  candidates: "Heavy-duty gentleness" · "From the workshop, not the lab" · "Built for difficult skin"
P2 sub-positioning (eyelid): shippable consumer framing — "Purpose-made for the delicate eyelid area — non-steroid, and formulated for comfort on the most reactive skin." (The original "flares your treatment doesn't clear" line survives as internal strategy only — as consumer copy it's a therapeutic claim. Post red-team fix.)
Personas DURABLE ARCHETYPES — PRODUCTS MAP ONTO THEM
Defined by each person's enduring relationship with their skin (severity, mindset, life-role), not by which SKU they buy — so the set holds as the brand expands. 3 core + 1 expansion. Grounded in the 469-item research.
"Jordan" — The Severe / Systemic
Core · medical-maximalist · high LTV
IdentityLifelong severe eczema; on a biologic (Dupixent/Rinvoq); pro-medicine, anti-hype.
RealityBiologic clears the body — face & eyes still flare ("Dupixent eyes"). High medical literacy.
WantsNon-steroid, eye-safe, comfortable relief for what the meds don't reach. Honest complement, never an alternative.
Maps toToday: P2 eye + P1 body · Future: adjuncts across the range
"Maya" — The Moderate Self-Manager
Core · the volume segment
IdentityModerate eczema, no biologic. Tacrolimus + emollients; deliberately steroid-cautious (TSW/thinning).
Key tensionTacrolimus is eye-safe — but burns like hell. Adherence suffers. The greasing grind.
WantsNon-steroid, non-burning soothing she can use anywhere; a routine that's bearable and dignified.
Maps toToday: P1 body + P2 eye · Future: core buyer of most SKUs
"Sam" — The Sensitive / Lifestyle
Growth · non-clinical · brand-led
IdentitySensitive/reactive skin (not clinical). Barrier-care enthusiast; skin as self-care, not burden.
RealityRides the K-beauty wave; values aesthetics AND ingredients. TikTok / Mecca / Adore.
WantsBarrier care that's effective and beautiful, from a brand with a story.
Maps toToday: P1 + gateway · Future: adjacent categories
"Hannah" — The Caregiver
Expansion (future) · not the user, the decision-maker
IdentityParent of a child with eczema. Emotionally charged, high-stakes, research-obsessed.
RealitySleepless nights, scratching child, amplified steroid fear (won't use strong steroids on a baby).
WantsSomething safe, gentle, trustworthy. Reassurance as much as product.
Maps toToday: not served (adult products) · Future: baby / kids / family line
Sharpest product insight: the two clinical archetypes (Jordan, Maya) both converge on the eye area, where the unmet need is non-steroid + non-burning. Steroids are comfortable but unsafe near eyes; tacrolimus is eye-safe but stings. P2 owns the space between them.
Brand Aperture ECZEMA NOW → SENSITIVE LATER
Beachhead strategy: own the hardest customer first (eczema), then widen. Sharp tip, broad base — products map onto the rings, the aperture opens outward over time.
Expansion (future)
Hannah — Caregiver → baby/kids/family
Halo — sensitive/reactive
Sam — the "Tower 28" audience
Core — eczema
Jordan · Maya
"If it's gentle enough for eczema, it's gentle enough for anyone with sensitive skin."
Eczema-specificity isn't a ceiling — it's the proof point that earns the broad audience. Win the hardest case; the wider sensitive-skin market trusts you because of it.
The name helps: "Spanner Skin" (not Beauty) is an open-ended umbrella — eczema → sensitive → skin-health, never boxed into makeup. A wider runway than Tower 28 Beauty.
Guardrail: don't widen too fast — generic "sensitive" won't hold a premium. Sequence: own eczema → earn authority → widen deliberately.
Brad's Playbook THE 3-STEP SPINE
Talia's dad Brad's repeatable method for validating a business via expert advisors before launch. Goal: complete all three within ~3 months.
STEP 1
Executive Summary
One-page business summary used to introduce Spanner Skin to dermatologist advisors.
Not started
STEP 2
SWOT Analysis
Evidence-backed strengths, weaknesses, opportunities, threats — see below.
✓ Done
STEP 3
Dermatologist Outreach
Email top 3–5 women dermatologists (Melbourne/Sydney) for advice — not a pitch, not money. Vanessa Morgan already a connection.
Not started
SWOT EVIDENCE-BACKED
Built on the competitor sweep (27 brands), the 469-item community research, and the BOV market-gap analysis.
💪 Strengths
  • Authentic founder–market fit — lifelong eczema, on Dupixent. The exact derm-outreach hook.
  • First-mover on premium BOV spray for eczema in AU — only Curél/Aquaphor occupy it, neither premium-AU.
  • Format solves named pain — no-touch spray answers "greasing" friction + "burns on broken skin".
  • Ownable brand identity — owns desirability, which no AU eczema brand does.
  • Validated P2 (eyelid) — 7× confirmed gap + the biologics buyer.
  • Evidence engine + relevant day job (Adore Beauty, tech/SEO).
⚠ Weaknesses
  • Pre-everything — pre-revenue, pre-formulation, solo, alongside a job.
  • No in-house formulation — BOV is complex + expensive to produce.
  • Capital constraints — tooling, MOQs, EAA cert all cost money.
  • Zero awareness — social handles not yet secured.
  • Cosmetic claim limits — can't say "treats/heals" (what sufferers search).
  • No derm advisor yet — credibility gap (Brad's step 3 pending).
🚀 Opportunities
  • Open AU lane — no beloved AU eczema brand; Dermeze failing; people repurpose Bepanthen.
  • P2 + biologics wave — Dupixent crowd clears body, battles face/eye, wants non-steroid topical.
  • K/J-beauty body-care wave reaching AU — proves appetite, availability gap.
  • Proven prestige retail paths — Nécessaire/Tower 28 (Sephora), Bangn Body (Mecca); Adore is Talia's channel.
  • Cheap community trust + derm advisor network (Vanessa Morgan).
  • EAA certification as a launch trust anchor.
🛡 Threats
  • Entrenched incumbents — QV/MooGoo/Ego cheap + trusted; CeraVe is derm default.
  • Well-funded entrants — Nécessaire/Curél/Aquaphor could take the BOV gap.
  • BOV supply-chain risk — few AU aerosol makers, high MOQs, propellant rules.
  • Regulatory drift — ACCC claims crackdown / TGA reclassification risk.
  • High trust bar — sufferers burned by hype; price compression from pharmacy dupes.
  • Derms may have own product lines — possible conflict.
Red Team Stress-Test 6 JUL 2026 — TRIED TO BREAK IT
Adversarial review of the whole foundation before derm outreach. Four critical cracks found — none fatal, all fixable. Full report in the vault.
🔴 Critical — fix before derm outreach
  • "Eczema" is a regulated word. Cosmetics can only say "eczema-prone skin" — AU incumbents saying "eczema" on pack hold AUST L listings. Claims architecture needed (EAA seal, copy discipline, maybe AUST L later). Perfect advisor question for the derms.
  • The biologics wedge is small in AU absolute numbers (low tens of thousands). Reframe: Jordan = beachhead & megaphone; Maya's broader eye-area population = the actual P2 market.
  • White space is narrower than framed. Hypochlorous sprays (Tower 28 SOS), thermal mists & Curél already serve the "no-touch spray" job. Fix (Talia's call): two angles, both kept — experience-led (the spritz/no-touch feel) for brand moments, outcome-led ("moisture that stays") for comparative moments. Only hard rule: never headline the jargon "BOV".
  • BOV economics still unexamined. MOQs, few AU fillers, viscosity feasibility. One manufacturer quote gates the P1-vs-P2 call. Cheap intel — get it.
✅ What survives (the important stuff)
  • Founder–market fit — unassailable, unreplicable.
  • The sensory insight ("feels everything", no-touch, dignity) — real, differentiated, and regulation-proof: you can always own how it feels.
  • The eye-area gap (non-steroid + non-burning) — survives the TAM haircut; Maya's population carries it.
  • The desirability gap in AU + the aperture logic — the regulatory constraint actually reinforces "eczema-prone/reactive" as both the legal phrasing and the wider market.
  • The name — no claims, no ceiling.
Serious (fix soon): research skews US/severe — thin AU data · "non-stinging" can't be promised as an absolute · premium price untested vs community price sensitivity · scope creep — the P1-vs-P2 call is the scope-control mechanism, not polish.
Strategic Priorities WHAT THE SWOT TELLS US TO DO
Cross-linking the quadrants turns the lists into action.
1
Use the founder story + derm advisors to beat the trust/awareness weakness. Talia's authentic eczema/Dupixent story + a named dermatologist advisor counter "no awareness" and "no credibility." Execute Brad's outreach next. S→W, O
2
Lead with P2 (eyelid) to the biologics community. Most-validated gap meets the most motivated, underserved, higher-income buyer. A defensible wedge big players ignore. S×O
⚠ Superseded (Sep): Talia's steer is now P1 leads — P1 is the hero, P2 also a hero and still the biologics-community play. Locked 25 Sep (Decision #10).
3
Make format + brand the moat, not ingredients. Incumbents and dupes win on price/parity; Spanner Skin wins on BOV experience + desirability. Don't compete on cheapness. S vs T
4
De-risk the BOV supply chain early. The biggest execution risk — validate AU/contract BOV manufacturers + MOQs before over-committing to brand build. W×T
5
Build community equity now, cheaply — claims-free. An honest, genuinely-helpful Reddit/TikTok presence pre-launch converts the cheap-trust opportunity. Never "miracle"/anti-medicine framing. ⚠️ Guardrail (verified TGA guidance): attaching product claims to condition-community placements can convert them to therapeutic — in eczema communities, be helpful as people, never as product ads. O
6
Pursue EAA certification as the trust anchor. Neutralises the incumbent trust advantage at launch. O vs T
⚠ Correction (6 Jul): EAA is now a tiered “Proud Partner” sponsorship logo, not a certification. Don't market as “EAA approved”. The stronger free move: formulate against the NEA Ecz-clusion list from day one.
Open Strategic Questions FROM TALIA'S 14 SEP BRAIN DUMP — PARKED (PRODUCT FIRST)
Big calls still open, but parked: Talia (25 Sep) wants to understand the products — ingredients, research, dermatologists — before any launch planning. Captured in Obsidian: 00 - BRAND FOUNDATION / Founder Brain Dump — 2026-09-14.
?
Launch in AU or the US? People keep saying the US is bigger; Talia leans AU — “it would be epic to take the challenge of launching a brand in Australia, even with a smaller market” (25 Sep), and a US launch doesn't feel doable from here. Decision B (regulatory path) now waits on this call, because the market decides which seal matters (NEA in the US, EAA in AU). The market choice shapes the regulatory path, the competitor set and distribution. Visa restrictions on the actual launch are acknowledged as a later issue. OPEN
?
How to launch without upfront capital? Talia wants a bootstrap pathway. Founder Learnings already point one way: get to profit on small volume first (P2 can launch from ~500 units), then raise from your own network if wanted — see Emma Grede + Amy Liu on the Research Hub. OPEN
→
Chip away in the background: due diligence on manufacturers, component (bottle/tube) makers and chemists · networking coffees (ophthalmologists, dermatologists, TSW community, eczema community, female founders) · later: Kate Morris / Delta Labs, Seedling, Sephora Accelerate. ONGOING